open access

Vol 10, No 6 (2014)
Case report
Published online: 2015-01-07
Get Citation

Durable response to fulvestrant therapy in a hormone receptor-positive metastatic breast cancer patient with massive metastatic disease

Bogumiła Czartoryska-Arłukowicz
Onkol. Prak. Klin 2014;10(6):344-346.

open access

Vol 10, No 6 (2014)
CASE REPORTS
Published online: 2015-01-07

Abstract

The choice of treatment modality in metastatic breast cancer depends on an age, performance status of the patient, comorbidities, disease dynamics, localization and number of metastatic lesions as well as an expression of hormonal receptors and HER2 receptor. Here we present the case of hormone receptor-positive postmenopausal metastatic breast cancer patient with the massive extension of the disease at presentation who were treated with fulvestrant, an estrogen receptor antagonist, after the failure of initial chemotherapy. Treatment with fulvestrant was associated with a significant improvement in physical status of the patient, weight gain, mobility and reduction of bone pain. Moreover, remission of the metastatic disease was durable.

Abstract

The choice of treatment modality in metastatic breast cancer depends on an age, performance status of the patient, comorbidities, disease dynamics, localization and number of metastatic lesions as well as an expression of hormonal receptors and HER2 receptor. Here we present the case of hormone receptor-positive postmenopausal metastatic breast cancer patient with the massive extension of the disease at presentation who were treated with fulvestrant, an estrogen receptor antagonist, after the failure of initial chemotherapy. Treatment with fulvestrant was associated with a significant improvement in physical status of the patient, weight gain, mobility and reduction of bone pain. Moreover, remission of the metastatic disease was durable.

Get Citation

Keywords

breast cancer, hormonotherapy, fulvestrant

About this article
Title

Durable response to fulvestrant therapy in a hormone receptor-positive metastatic breast cancer patient with massive metastatic disease

Journal

Oncology in Clinical Practice

Issue

Vol 10, No 6 (2014)

Article type

Case report

Pages

344-346

Published online

2015-01-07

Bibliographic record

Onkol. Prak. Klin 2014;10(6):344-346.

Keywords

breast cancer
hormonotherapy
fulvestrant

Authors

Bogumiła Czartoryska-Arłukowicz

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl